PMID- 18158774
OWN - NLM
STAT- MEDLINE
DCOM- 20080317
LR  - 20231213
IS  - 1084-9785 (Print)
IS  - 1084-9785 (Linking)
VI  - 22
IP  - 6
DP  - 2007 Dec
TI  - Induction of cytotoxic T-lymphocytes specific for malignant glioma by HLA 
      dimer-based artificial antigen-presenting cells.
PG  - 826-35
AB  - AIM: The aim of this study was to investigate the novel approach for targeting 
      malignant glioma. METHODS: Interleukin-13 receptor alpha2 (IL-13Ralpha2)-specific 
      cytotoxic T-cells (CTLs) were induced from the peripheral blood lymphocytes 
      (PBLs) of human leukocyte antigen (HLA)-A2 positive healthy donors by multiple 
      stimulations with artificial antigen-presenting cells (aAPCs) made by coating 
      HLA-A2-Ig/pIL-13Ralpha2(345-354) dimeric complexes, anti-CD28 antibody, and CD83 
      molecules to cell-sized latex beads. RESULTS: The induced CTLs exhibited a 
      specific lysis against T2 cells pulsed with the peptide pIL-13Ralpha2(345-354) 
      and HLA-A2(+) glioma cells expressing IL-13Ralpha2(345-354), while HLA-A2(-) 
      glioma cell lines that express IL-13Ralpha2(345-354) could not be recognized by 
      the CTLs. The peptide-specific activity was inhibited by the anti-HLA class I 
      monoclonal antibody. CONCLUSIONS: The induced CTLs specific for the 
      IL-13Ralpha2(345-354) peptide could be a potential target of specific 
      immunotherapy for HLA-A2(+) patients with malignant glioma.
FAU - Xiaobing, Jiang
AU  - Xiaobing J
AD  - Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China. jxb917@126.com
FAU - Xiaoling, Lu
AU  - Xiaoling L
FAU - Ruen, Liu
AU  - Ruen L
FAU - Fangcheng, Zhang
AU  - Fangcheng Z
FAU - Hongyang, Zhao
AU  - Hongyang Z
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Biother Radiopharm
JT  - Cancer biotherapy & radiopharmaceuticals
JID - 9605408
RN  - 0 (Antibodies)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, CD)
RN  - 0 (CD28 Antigens)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Immunoglobulins)
RN  - 0 (Interleukin-13 Receptor alpha2 Subunit)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Peptide Fragments)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Antibodies/chemistry/immunology
MH  - Antibodies, Monoclonal/immunology/pharmacology
MH  - Antigen Presentation/*immunology
MH  - Antigens, CD/chemistry/immunology
MH  - CD28 Antigens/immunology
MH  - CD8-Positive T-Lymphocytes/cytology/immunology/metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cytotoxicity, Immunologic/drug effects/immunology
MH  - Epitopes, T-Lymphocyte/chemistry/immunology
MH  - Gene Expression
MH  - Glioma/*immunology/pathology/therapy
MH  - HLA-A2 Antigen/*immunology
MH  - Histocompatibility Antigens Class I/immunology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Immunoglobulins/chemistry/immunology
MH  - Interferon-gamma/metabolism
MH  - Interleukin-13 Receptor alpha2 Subunit/genetics/*immunology
MH  - Leukocytes, Mononuclear/immunology
MH  - Lymphocyte Activation/immunology
MH  - Membrane Glycoproteins/chemistry/immunology
MH  - Microspheres
MH  - Peptide Fragments/chemistry/immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology/metabolism
MH  - CD83 Antigen
EDAT- 2007/12/27 09:00
MHDA- 2008/03/18 09:00
CRDT- 2007/12/27 09:00
PHST- 2007/12/27 09:00 [pubmed]
PHST- 2008/03/18 09:00 [medline]
PHST- 2007/12/27 09:00 [entrez]
AID - 10.1089/cbr.2007.0406 [doi]
PST - ppublish
SO  - Cancer Biother Radiopharm. 2007 Dec;22(6):826-35. doi: 10.1089/cbr.2007.0406.